I-PAS Goggles for Concussion Diagnosis

EW
Overseen ByErin Williams
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Miami
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if the I-PAS goggles, a diagnostic device, can accurately diagnose mild traumatic brain injuries (mTBI), such as concussions, in settings like emergency rooms or urgent care. Participants include individuals with a recent head impact causing changes in consciousness and symptoms like dizziness, as well as a control group with minor injuries, such as sprained ankles. Ideal participants have recently experienced a mild head injury or minor non-head injury and are seeking care. As an unphased trial, this study provides participants the opportunity to contribute to the advancement of diagnostic tools for brain injuries.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the I-PAS Goggles are safe for diagnosing mTBI?

Research has shown that the I-PAS Goggles are safe for use. The FDA has approved these goggles for diagnosing mild traumatic brain injury (mTBI), confirming their safety for this purpose. The goggles track eye movements to perform tests, which do not involve surgery or cutting and are considered low risk. Previous studies have described the device as having "non-significant risk," indicating it is unlikely to cause harm. Overall, users have reported no major problems with the goggles.12345

Why are researchers excited about this trial?

Researchers are excited about the I-PAS Goggles because they offer a new way to diagnose concussions quickly and accurately. Traditional methods, like cognitive tests and symptom checklists, can be subjective and time-consuming. But these goggles use eye-tracking technology to detect subtle changes in eye movements that are often missed by standard tests. This innovative approach could lead to faster and more reliable concussion diagnoses, helping patients receive appropriate care sooner.

What evidence suggests that the I-PAS Goggles are effective for diagnosing mTBI?

Research has shown that the I-PAS Goggles have received FDA approval for diagnosing mild traumatic brain injury (mTBI). These goggles use advanced technology to track eye movements, which can change after a brain injury. In this trial, participants with mTBI will undergo testing with the I-PAS Goggles to help identify the presence of an mTBI. The goggles have proven effective in diagnosing brain injuries quickly and accurately in emergency situations, making them a valuable tool.34567

Who Is on the Research Team?

Dr. Michael Ellis Hoffer, MD - Miami ...

Michael E Hoffer, MD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

This trial is for adults aged 18-50 who've had a head impact and are diagnosed with mild traumatic brain injury (mTBI) or concussion at specific hospitals. It's also for similar adults without head injuries as controls. Excluded are those with severe injuries, past significant head trauma, certain medical conditions, or inability to consent.

Inclusion Criteria

I am 18-50 years old and was diagnosed with a concussion after a head injury.
I am a control participant with minor injuries, not involving the head, and not needing hospital stay.

Exclusion Criteria

I am unable to understand and agree to the study's details on my own.
I have had a head injury from something piercing my skull.
You have had a head injury where you were unconscious for more than 59 minutes.
See 13 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Testing

Participants undergo testing with the I-PAS Goggles to diagnose mTBI or assess minor injuries

1 day
1 visit (in-person)

Follow-up

Participants are monitored for recovery and readiness to return to normal activity after a head injury

33 months

What Are the Treatments Tested in This Trial?

Interventions

  • I-PAS Goggles
Trial Overview The study tests the I-PAS Goggle System's ability to diagnose mTBI in community healthcare settings like emergency departments. Researchers want to see if it works reliably outside of traditional hospital environments.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Subjects with mTBIExperimental Treatment1 Intervention
Group II: Subjects with minor injuriesActive Control1 Intervention

I-PAS Goggles is already approved in United States for the following indications:

🇺🇸
Approved in United States as I-PAS for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials
976
Recruited
423,000+

Neurolign

Industry Sponsor

Trials
8
Recruited
2,000+

Published Research Related to This Trial

Visual symptoms like photophobia and blurred vision are common in concussion patients, highlighting the importance of eye movement control areas in the brain that are vulnerable to injury.
Testing vision and eye movements can be a reliable method for detecting concussions and monitoring recovery, helping guide treatment decisions and rehabilitation strategies.
Neuro-ophthalmologic disorders following concussion.Debacker, J., Ventura, R., Galetta, SL., et al.[2019]
Concussions can cause subtle changes in brain function, particularly affecting balance, cognition, and vision, which can be detected through specialized visual tests like the King-Devick (K-D) test.
Combining visual assessments with cognitive and balance tests, as well as advanced techniques like neuroimaging, enhances our ability to identify concussions and make informed return-to-play decisions, potentially reducing the risk of long-term effects.
The Concussion Toolbox: The Role of Vision in the Assessment of Concussion.Ventura, RE., Balcer, LJ., Galetta, SL.[2022]
In a study of 30 children aged 5-15 with neuro-ophthalmic disease, Goldmann perimetry was completed successfully by 90% of participants, compared to 72.4% for Octopus perimetry, indicating Goldmann may be more feasible for this population.
While both perimetry methods showed broad agreement in visual field outputs, Octopus perimetry tended to underestimate severe visual field defects, which could affect the consistency of assessments over time.
Study of Optimal Perimetric Testing in Children (OPTIC): evaluation of kinetic approaches in childhood neuro-ophthalmic disease.Patel, DE., Cumberland, PM., Walters, BC., et al.[2020]

Citations

Study Details | NCT04372797 | Standardized Instruments ...The I-PAS Goggles are FDA approved for the diagnosis of mTBI. Individuals will undergo a subset of tests from the tests listed below. Tests: Explanation/eye ...
I-PAS Goggles for Concussion DiagnosisThis trial tests if the I-PAS goggle system can reliably diagnose mild brain injuries in urgent care or emergency settings.
I-PAS 'goggles test' provides major advancement in ...The I-Portal Portable Assessment System, commonly referred to as the “goggles test,” runs high-quality diagnostic tests to evaluate patients with symptoms of ...
Normative data for ages 18‐45 for ocular motor and vestibular ...This normative database can serve as a tool to aid in diagnosis, treatment, and/or rehabilitation protocols for vestibular and neurological conditions, ...
Concussion Testing (I-PAS) Dallas, TXI-PAS testing is a diagnostic exam that uses virtual reality goggles to track eye movements. When the brain is injured, these movements often change in ways ...
Study Details | NCT02486003 | Testing mTBI in AthletesThe IPAS goggles are programmed with a series of tests that track eye motions in response to a target. This device has been determined to be a Non-Significant ...
I-PAS™ chosen by Department of Defense to baseline ...I-PAS was cleared by the U.S. Food and Drug Administration (FDA) in November 2017, predicated on NKI's cleared I-Portal Neurotologic Testing ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security